{"nctId":"NCT04660643","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss","startDateStruct":{"date":"2021-03-29","type":"ACTUAL"},"conditions":["Obesity","Overweight"],"count":783,"armGroups":[{"label":"Tirzepatide (lead-in)","type":"EXPERIMENTAL","interventionNames":["Drug: Tirzepatide"]},{"label":"Tirzepatide MTD","type":"EXPERIMENTAL","interventionNames":["Drug: Tirzepatide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Tirzepatide","otherNames":["LY3298176"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Body Mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease\n* History of at least one unsuccessful dietary effort to lose body weight\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Change in body weight greater than 5 kg within 3 months prior to starting study\n* Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity\n* History of pancreatitis\n* Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years\n* Any lifetime history of a suicide attempt","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Randomization in Body Weight at Week 88","description":"Least square (LS) mean was analysed by mixed model repeated measures (MMRM) model with randomization + analysis country + sex + interactive web response system (IWRS) MTD at Week 36 + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"0.53"},{"groupId":"OG001","value":"-6.7","spread":"0.52"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Randomization in Body Weight at Week 64","description":"LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"0.38"},{"groupId":"OG001","value":"-6.0","spread":"0.37"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization in Body Weight","description":"LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"0.43"},{"groupId":"OG001","value":"-5.7","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization in Waist Circumference","description":"LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"0.44"},{"groupId":"OG001","value":"-4.6","spread":"0.43"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization in Body Mass Index (BMI)","description":"LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"0.16"},{"groupId":"OG001","value":"-2.1","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization in Fasting Glucose","description":"LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.74","spread":"0.548"},{"groupId":"OG001","value":"-0.90","spread":"0.528"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization in Hemoglobin A1c (HbA1c)","description":"LS mean was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"0.017"},{"groupId":"OG001","value":"-0.08","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Randomization in Fasting Insulin","description":"LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":"4.37"},{"groupId":"OG001","value":"-15.4","spread":"2.88"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Randomization in Lipid Parameters (Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Very Low Density Lipoprotein (VLDL) Cholesterol, Triglycerides, Free Fatty Acids (FFA))","description":"LS mean was analysed by MMRM model with log(actual measurement/randomization) = log (randomization) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.30","spread":"0.943"},{"groupId":"OG001","value":"2.29","spread":"0.852"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.43","spread":"1.368"},{"groupId":"OG001","value":"-3.36","spread":"1.218"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":"1.06"},{"groupId":"OG001","value":"18.3","spread":"1.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"2.32"},{"groupId":"OG001","value":"-7.8","spread":"1.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":"2.39"},{"groupId":"OG001","value":"-8.2","spread":"1.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"2.98"},{"groupId":"OG001","value":"-13.4","spread":"2.54"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)","description":"LS mean change was analysed by MMRM model with randomization + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"0.64"},{"groupId":"OG001","value":"2.1","spread":"0.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"0.44"},{"groupId":"OG001","value":"-0.4","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form - Physical Functioning Domain Score","description":"The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores.\n\nLS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\\< 10%, \\>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.32"},{"groupId":"OG001","value":"0.8","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Function Composite Score","description":"The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency (\"never\" to \"always\") scale or a 5-point truth (\"not at all true\" to \"completely true\") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life.\n\nLS mean was analysed by ANCOVA model with randomization + analysis Country + sex + weight loss at Week 36 (\\< 10%, \\>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"0.95"},{"groupId":"OG001","value":"4.4","spread":"0.91"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintain at Least 80% of the Body Weight Lost During the Open-Label Lead-In Period","description":"Percentage of Participants Who Maintain at least 80% of the Body Weight Lost During the Open-Label Lead-In Period was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\\*Time as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.50","spread":null},{"groupId":"OG001","value":"93.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline","description":"Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction from baseline was analysed by Logistic regression model with missing value imputed by MMRM at week 88. Missing values were imputed by predictions using observed data in the efficacy analysis set from the same treatment group through an MMRM analysis model for post-baseline measures with Baseline + Analysis Country + Sex + IWRS MTD at Week 36 + randomization + Treatment + Time + Treatment\\*Time as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.00","spread":null},{"groupId":"OG001","value":"98.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.38","spread":null},{"groupId":"OG001","value":"93.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.01","spread":null},{"groupId":"OG001","value":"87.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.55","spread":null},{"groupId":"OG001","value":"72.59","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Occurrence of Participants Returning to >95% Baseline Weight for Those Who Lost ≥5% During the Open-Label Lead-In Period","description":"Time to first occurrence of participants returning to \\>95% baseline weight for those who lost ≥5% during the open-label lead-in period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in BMI","description":"LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + BMI at randomization (kg/m\\^2) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"0.16"},{"groupId":"OG001","value":"-10.0","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"0.43"},{"groupId":"OG001","value":"-27.6","spread":"0.42"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Body Weight","description":"LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + body weight at randomization (kg) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.5","spread":"0.40"},{"groupId":"OG001","value":"-26.0","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference","description":"LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":"0.53"},{"groupId":"OG001","value":"-22.8","spread":"0.52"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Glucose","description":"LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.72","spread":"0.543"},{"groupId":"OG001","value":"-10.63","spread":"0.522"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c","description":"LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.018"},{"groupId":"OG001","value":"-0.57","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Insulin","description":"LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.8","spread":"2.52"},{"groupId":"OG001","value":"-54.1","spread":"1.57"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipid Parameters (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides, FFAs)","description":"LS mean was analysed by MMRM model with log(actual measurement/baseline) = log (baseline) + analysis country + sex + IWRS MTD at Week 36 + weight loss at week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":"0.919"},{"groupId":"OG001","value":"-5.01","spread":"0.817"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.62","spread":"1.371"},{"groupId":"OG001","value":"-5.21","spread":"1.207"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.44","spread":"1.093"},{"groupId":"OG001","value":"12.29","spread":"1.071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.6","spread":"1.82"},{"groupId":"OG001","value":"-32.6","spread":"1.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.3","spread":"1.84"},{"groupId":"OG001","value":"-33.3","spread":"1.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.69","spread":"2.811"},{"groupId":"OG001","value":"-20.38","spread":"2.360"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SBP, DBP","description":"LS mean was analysed by MMRM model with baseline + analysis country + sex + IWRS MTD at Week 36 + Weight Loss at Week 36 (\\< 10%, \\>= 10%) + treatment + time + treatment\\*time (Type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"0.66"},{"groupId":"OG001","value":"-9.3","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.46"},{"groupId":"OG001","value":"-5.5","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SF 36v2 Acute Form - Physical Functioning Domain Score","description":"The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores.\n\nLS mean was analysed by analysis of covariance (ANCOVA) model with randomization + analysis Country + sex + weight loss at Week 36 (\\< 10%, \\>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"0.36"},{"groupId":"OG001","value":"6.3","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in IWQOL-Lite-CT - Physical Function Composite Score","description":"The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency (\"never\" to \"always\") scale or a 5-point truth (\"not at all true\" to \"completely true\") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life.\n\nLS mean was analysed by ANCOVA model with baseline + analysis Country + sex + weight loss at Week 36 (\\< 10%, \\>= 10%) + IWRS MTD at Week 36 + treatment (type III sum of squares) as variables.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"1.01"},{"groupId":"OG001","value":"26.0","spread":"0.97"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":782},"commonTop":["Nausea","Diarrhoea","Constipation","Covid-19","Vomiting"]}}}